REUNIÓN STREAMING

Novedades y Claves 2020 en CÁNCER de PULMÓN

INTRODUCCIÓN

Virginia Calvo

Hospital Universitario Puerta de Hierro Majadahonda

Organizado por:

GECP lung cancer research

PROGRAMA CIENTÍFICO

- Introducción

  Dra. Virginia Calvo

  Hospital Universitario Puerta de Hierro Majadahonda, Madrid

- Biomarcadores pronósticos

  Dra. Marta Domènech

  ICO Badalona, Barcelona

- Estadios iniciales y enfermedad localmente avanzada

  Dr. Carlos Gálvez

  Hospital General Universitario de Alicante

- Enfermedad metastásica (incluyendo inmunoterapia)

  Dr. Francisco Aparisi

  Hospital General Universitario de Valencia

- Cáncer de pulmón microcítico y otros tumores

  Dr. Carlos Aguado

  Hospital Clínico San Carlos, Madrid

- Conclusiones

  Dra. Remei Blanco

  Hospital de Terrassa, Barcelona

BIOMARCADORES PRONÓSTICOS

Marta Domènech

Institut Català d'Oncologia- Hospital Germans Trias y Pujol

Organizado por:
GECP
lung cancer research

NON-SMALL CELL LUNG CANCER

IMMUNOTHERAPY

- PD-L1: predictive biomarker
- An analysis of the first 100 patients from the PIONeeR Project: > 400 biomarker data

Precision Immuno-Oncology for advanced NSCLC patients treated with PD(L)1 immune checkpoint inhibitors (ICIs)

An analysis of the first 100 pts from the **PIONeeR Project**



NON-SMALL CELL LUNG CANCER

MOLECULAR BIOMARKERS

- Identification of actionable mutations and development of targeted therapies for precision medicine



Adapted from Tsao, et al. J Thorac Oncol 2016; Dearden, et al. Ann Oncol 2013
Bevacizumab SmPC 2018; clinicaltrials.gov

SMALL CELL LUNG CANCER

- Recent SCLC biomarkers hold considerable promise for precision medicine
- Urgent need to profile large cohorts of SCLC to define the common subtypes

Emerging transcription-factor subsets of SCLC provide a path forward for personalizing treatment



	ASCL1	NEUROD1	POU2F3	YAP1
Targeted Therapies	BCL2 CREBBP DLL3 LSD1	Arginine Deprivation AURKA/B CHK1 IMPDH LSD1	Arginine Deprivation AURKA/B CHK1 IGF-R1 IMPDH	Arginine Deprivation AURKA/B CHK1 IMPDH IO
	Abstract 9018			Abstract 9019

Poirier et al, JTO 2020



Carl Gay, WCLC 2019

Slides are the property of the author, permission required for reuse.

ESTADIO INICIALES
ENFERMEDAD LOCALMENTE AVANZADA

Carlos Gálvez

Hospital General Universitario Alicante

Organizado por:
GECP
lung cancer research

EARLY STAGE

NEOADJUVANT

- SAKK 16/14: a multicenter single-arm, phase II trial: durvalumab in addition to neoadjuvant chemotherapy in patients with stage III (N2) NSCLC
- IFCT-1601 IONESCO: a multicenter study: neoadjuvant durvalumab in stage IB ≥ 4cm, II and IIIA resectable NSCLC
- PRINCEPS trial: a phase II trial of neoadjuvant atezolizumab for resectable NSCLC (stage I (T≥2cm)-IIIA)

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Mariano Provencio, Ernest Nadal, Amelia Insa, María Rosario García-Campelo, Joaquín Casal-Rubio, Manuel Dómine, Margarita Majem,

CrossMark

GECP lung cancer research

EARLY STAGE

ADJUVANT THERAPY IN PATIENTS WITH RESECTED EGFR MUTATED (EGFRm) NSCLC





ADAURA:

Osimertinib adjuvant therapy in patients with resected EGFRm NSCLC

Central Nervous System (CNS) disease recurrence

CTONG 1104:

Gefitinib adjuvant therapy in patients with resected EGFRm NSCLC

EARLY STAGE

ADJUVANT RT (PORT)

- LUNG-ART: PORT vs No PORT en CPCNP resecables con afectación N2



LOCALLY ADVANCED DISEASE

IMMUNOTHERAPY

- PACIFIC trial: 4-year survival update

Phase 3, Randomised, Double-blind, Placebo-controlled, Multicentre, International Trial



- Updated analyses of OS and PFS (~4 years after the last patient was randomised; planned exploratory update)
  - Treatment effects for the ITT population were estimated using a stratified log-rank approach (with trial stratification factors)
  - Treatment effects for patient subgroups were estimated from unstratified Cox proportional-hazards models (with treatment as the only covariate)

- PACIFIC R: first real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy

- 1242P Characteristics of the first 615 patients enrolled

LOCALLY ADVANCED DISEASE

TARGETED THERAPIES

WJOG 6911L: a single-arm phase II study of gefitinib with concurrent thoracic radiotherapy in unresectable locally-advanced NSCLC patients with EGFR mutation

<WJOG6911L> Key Inclusion Criteria

- Treatment-naïve
- Unresectable, locally advanced NSCLC
- With EGFR mutation (19del or L858R)
- Age < 75 y.o.
- ECOG PS 0-1

↓

Gefitinib 250 mg/day, 2 years
+
Concurrent thoracic radiotherapy 64Gy / 32frs
(N = 27)

- **Primary endpoint**: Progression-free survival (PFS) rate at 2 years
  Hypothesis and statistical consideration
  - ✓ Study treatment will improve PFS rate at 2 years from 20 to 40%, one-sided α; 0.05 and β; 0.25

  >> 27 patients were required
- **Secondary endpoints**: Overall response rate (ORR), PFS, overall survival (OS) and adverse events (AEs)

REUNIÓN STREAMING

Novedades y Claves 2020

en CÁNCER de PULMÓN

Enfermedad Metastásica

Francisco de Asís Aparisi Aparisi

Hospital General de Requena y Consorci Hospital General Universitario Valencia

Hospital General Universitari de Valencia

HRG

Hospital General Requena

Organizado por:

GECP lung cancer research

IMMUNOTHERAPY

- **Update**
  - Keynote-189: final analysis (Rodríguez Abreu - ASCO 2020)
  - Keynote-024: 5-year OS update (Brahmer JR – ESMO 2020)
- **New drugs**
  - ORIENT 11: Sintilimab (Zhang Li - WCLC 2020)
  - ORIENT 12: Sintilimab + Platinum/Gemcitabine (Zhou C – ESMO 2020)
  - Empower Lung 1: Cemiplimab (Sezer A – ESMO 2020)
- **New strategies**
  - ONO-4538-52/TASUKI-52: Nivolumab + Carbo-Taxol-Beva (Lee JS – ESMO 2020)
  - CheckMate 227: Nivolumab + Ipilimumab: 3-year update (Ramalingam S – ASCO 2020)
  - CheckMate 9LA: Nivolumab + Ipilimumab + 2 cycles of CT (Reck M – ASCO 2020)
  - CCTG BR.34: Durvalumab + Tremelimumab +/- CT (Natasha L – ASCO 2020)
  - WJOG10718L: Atezolizumab + Bevacizumab PDL1>50% (Seto T – ESMO 2020)
  - CITYSCAPE: Tiragolumab + Atezolizumab (Johnson M – ASCO 2020)

TARGETED THERAPIES

Overview of targeted therapies in 2020: the NEJM prism



CÁNCER DE PULMÓN MICROCÍTICO Y OTROS TUMORES

Carlos Aguado

Hospital Clínico San Carlos

Organizado por:

GeCP
lung cancer research

LIMITED STAGE SMALL-CELL LUNG CANCER

- A randomized phase II study comparing the efficacy of standard-dose with high-dose twice-daily thoracic radiotherapy in Limited Stage Small-Cell Lung Cancer



Gronberg BH, et al. ASCO 2020. ESMO 2020

LIMITED STAGE SMALL-CELL LUNG CANCER

- Results from the randomized phase II ETOP/IFCT 4-12 STIMULI trial: consolidation with nivolumab and ipilimumab vs observation in limited stage Small-Cell Lung Cancer after chemo-radiotherapy



Peters S, et al. ESMO 2020

EXTENDED STAGE SMALL-CELL LUNG CANCER: 1st Line









EXTENDED STAGE SMALL-CELL LUNG CANCER: 1st Line

- Addition of immune checkpoint blockade to chemotherapy is a new standard of care for ES-SCLC

1L ES-SCLC Chemo-IO Trial	Combination	Outcome Data Experimental Arm	Outcome Data Control Arm	HR
IMPower133	EP + Atezolizumab	mOS 12.3 mo	mOS 10.3 mo	0.70
CASPIAN	EP + Durvalumab	mOS 12.9 mo	mOS 10.5 mo	0.75
Keynote-604	EP + Pembrolizumab	mOS 10.8 mo	mOS 9.7 mo	0.80
ECOG-ACRIN EA5161 Randomized phase II	EP + Nivolumab	mPFS 5.5 mo mOS 11.3 mo	mPFS 4.6 mo mOS 8.5 mo	0.65 0.67

EXTENDED STAGE SMALL-CELL LUNG CANCER: 2nd Line

- RESILIENT part 1: an open-label, safety run-in of LIPOSOMAL IRINOTECANT in adults with SCLC who have progressed with platinum-based first-line therapy: subgroup analyses by platinum sensitivity

- ALTER 1202: a randomized, double-blind phase 2 trial, effect of ANLOTINIB in advanced SCLC patients relapsed within 3 months after second-line treatment

- CLEPSIDRA trial: final safety and efficacy IADADEMSTAT (epigenetic drug) + PE

MESOTHELIOMA: 1st Line

- First-line nivolumab + ipilimumab vs chemotherapy in unresectable malignant pleural mesothelioma: CheckMate 743 (Baas, WCLC 2020)



- PrE0505 Phase II multicenter study of anti-PD-L1 Durvalumab, in combination with Cisplatin and Pemetrexed for the First-Line Treatment of Unresectable MPM (Abstract 9003. Forde – ASCO 2020)

MESOTHELIOMA: 2nd Line

Randomized phase II study on Gemcitabine with or without Ramucirumab as second-line treatment for advanced MPM. Results of Italian RAMES study (Abstract 9004. Pagano – ASCO 2020)



Slides are the property of the author, permission required for reuse.

Añade la fecha a tu calendario

14 de diciembre

de 16:00h a 18:00h.

REUNIÓN STREAMING

Novedades y Claves 2020 en CÁNCER de PULMÓN

Programa científico

Introducción
Dra. Virginia Calvo
Hospital Univ. Puerta de Hierro Majadahonda (Madrid)

Biomarcadores pronósticos
Dra. Marta Domènech
ICO Badalona (Barcelona)

Estadios iniciales y enfermedad localmente avanzada
Dr. Carlos Gálvez
Hospital General Univ. de Alicante

Enfermedad metastática (incluyendo inmunoterapia)
Dr. Francisco Aparisi
Hospital General Univ. de Valencia

Cáncer de pulmón microcítico y otros tumores
Dr. Carlos Aguado
Hospital Clínico San Carlos (Madrid)

Conclusiones
Dra. Remei Blanco
Hospital de Terrassa (Barcelona)

Con la colaboración de :

Bristol Myers Squibb™

Takeda

Organizado por:

GECP lung cancer research